Mereo BioPharma’s Public Offering and Strategic Underwriter Partnership
Company Announcements

Mereo BioPharma’s Public Offering and Strategic Underwriter Partnership

Mereo Biopharma Group Plc (MREO) has shared an announcement.

Mereo BioPharma Group plc has partnered with key underwriters for a public offering of 12.5 million American Depositary Shares at $3.99 each, representing five ordinary shares per ADS. The company anticipates a net gain of roughly $45.9 million after expenses and expects the offering to close by June 17, 2024. This move is backed by a shelf registration statement with the SEC, and the underwriters are provided with customary indemnification rights. A recent press release details the offering’s pricing, underscoring the company’s proactive disclosure to investors.

Find detailed analytics on MREO stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyMereo BioPharma reports Q3 EPS (2c), consensus (2c)
TheFlyBiotech Alert: Searches spiking for these stocks today
TheFlyMereo BioPharma reports Q2 EPS (2c) vs 0c last year
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App